$1.41
+0.02 (+1.44%)
Open$1.40
Previous Close$1.39
Day High$1.43
Day Low$1.38
52W High$3.82
52W Low$0.56
Volume—
Avg Volume691.2K
Market Cap69.05M
P/E Ratio—
EPS$-0.83
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+904.3% upside
Current
$1.41
$1.41
Target
$14.16
$14.16
$9.87
$14.16 avg
$18.59
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.87M | 3.13M | 19.24M |
| Net Income | -85,723,915 | -129,232,032 | -3,136,016 |
| Profit Margin | -4,594.3% | -4,364.5% | -16.3% |
| EBITDA | -83,250,733 | -132,476,040 | -4,591,050 |
| Free Cash Flow | — | — | -2,958,449 |
| Rev Growth | -40.3% | -40.3% | -5.9% |
| Debt/Equity | 0.91 | 0.91 | 0.76 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |